Glenmark’s pursuit of innovative drug discovery started over two decades ago with a vision to find cures for the unmet medical needs of patients across the globe by providing novel therapeutic options.

Glenmark set up its first center focusing on small molecule research at Mahape, India in 2000, followed by a biologics research center in Switzerland in 2006. One of the pivotal moments in Glenmark’s innovation journey came in 2004 when it signed its first out-licensing deal with Forest Laboratories. Subsequently, over the years, Glenmark has struck multiple out-licensing deals with large multinationals for its small and biologics molecules in various stages of clinical development.

This marked a major step for Glenmark as it continued its drug discovery journey with a primary focus on expanding its oncology and immunotherapy pipeline.

In October 2019, Glenmark took the significant step of spinning its innovative biologics research division into a wholly-owned subsidiary, Ichnos Sciences Inc., an independent company headquartered in the USA, with a heightened focus on accelerating novel biologics entities (NBE) research.

To further explore groundbreaking solutions in the treatment of cancer, Glenmark and Ichnos took a collaborative leap in January 2024 and formed
‘Ichnos Glenmark Innovation’ (IGI). This alliance combines Glenmark’s research and development proficiencies in small molecule research with those of Ichnos in NBEs to develop cutting-edge therapy solutions that treat hematological cancers and solid tumors. IGI will use different modalities to treat cancer by going after bispecific and multispecific antibodies and small molecules. Harnessing the combined proficiency of over 150 scientists, IGI will leverage the capabilities of all its global centers of innovation. Going forward, all of Glenmark’s efforts in innovation will be channelized through IGI.

For further information on IGI, click here